Form 4: IOVA: Executive Receives Restricted Stock Units

Raj K. Puri, Chief Regulatory Officer of IOVANCE BIOTHERAPEUTICS, INC., was granted 15,000 restricted stock units on June 16, 2026, vesting over three years.

Summary

• Raj K. Puri, Chief Regulatory Officer at IOVANCE BIOTHERAPEUTICS, INC., received 15,000 restricted stock units (RSUs) on June 16, 2026.
• These RSUs are subject to a three-year vesting schedule.
• One-third of the RSUs will vest on the first anniversary of the grant date.
• The remaining RSUs will vest in eight equal quarterly installments over the subsequent two years, starting from the first quarter after the first anniversary.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event rather than a significant financial or strategic development.

Positives

• Grant of restricted stock units indicates a commitment to retaining key executive talent.
• The vesting schedule over three years aligns executive incentives with long-term company performance.

Future Outlook

The vesting schedule of the RSUs over three years suggests a forward-looking incentive tied to continued employment and company performance.

Industry Context

StockSavvy.ai notes that the issuance of restricted stock units to a Chief Regulatory Officer is a common practice in the biopharmaceutical industry to attract and retain senior leadership with specialized expertise crucial for navigating complex regulatory landscapes.

Stakeholder Impact

• Shareholders: The grant of RSUs is a form of compensation, impacting potential dilution if fully vested and exercised, but also aligns executive interests with shareholder value.

Next Steps

• Vesting of one-third of RSUs on the one-year anniversary of the grant date.
• Vesting of remaining RSUs in eight equal quarterly installments over the two years following the first anniversary.

Key Dates

Keywords

IOVANCE BIOTHERAPEUTICS, IOVA, Form 4, Restricted Stock Units, RSU, Executive Compensation, Vesting Schedule, Raj K. Puri, Chief Regulatory Officer